Artemether for severe malaria.

BACKGROUND: In 2011 the World Health Organization (WHO) recommended parenteral artesunate in preference to quinine as first-line treatment for people with severe malaria. Prior to this recommendation, many countries, particularly in Africa, had begun to use artemether, an alternative artemisinin derivative. This review evaluates intramuscular artemether compared with both quinine and artesunate.
OBJECTIVES: To assess the efficacy and safety of intramuscular artemether versus any other parenteral medication in treating severe malaria in adults and children. SEARCH
METHODS: We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library), MEDLINE, EMBASE and LILACS, ISI Web of Science, conference proceedings and reference lists of articles. We also searched the WHO clinical trial registry platform, ClinicalTrials.gov and the metaRegister of Controlled Trials (mRCT) for ongoing trials up to 9 April 2014. SELECTION CRITERIA: Randomized controlled trials (RCTs) comparing intramuscular artemether with intravenous or intramuscular antimalarial for treating severe malaria. DATA COLLECTION AND ANALYSIS: The primary outcome was all-cause death.Two authors independently assessed trial eligibility, risk of bias and extracted data. We summarized dichotomous outcomes using risk ratios (RR) and continuous outcomes using mean differences (MD), and presented both measures with 95% confidence intervals (CI). Where appropriate, we combined data in meta-analyses and assessed the quality of the evidence using the GRADE approach. MAIN
RESULTS: We included 18 RCTs, enrolling 2662 adults and children with severe malaria, carried out in Africa (11) and in Asia (7). Artemether versus quinine For children in Africa, there is probably little or no difference in the risk of death between intramuscular artemether and quinine (RR 0.96, 95% CI 0.76 to 1.20; 12 trials, 1447 participants, moderate quality evidence). Coma recovery may be about five hours shorter with artemether (MD -5.45, 95% CI -7.90 to -3.00; six trials, 358 participants, low quality evidence), and artemether may result in fewer neurological sequelae, but larger trials would be needed to confirm this (RR 0.84, 95% CI 0.66 to 1.07; seven trials, 968 participants, low quality evidence). Artemether probably shortens the parasite clearance time by about nine hours (MD -9.03, 95% CI -11.43 to -6.63; seven trials, 420 participants, moderate quality evidence), and may shorten the fever clearance time by about three hours (MD -3.73, 95% CI -6.55 to -0.92; eight trials, 457 participants, low quality evidence).For adults in Asia, treatment with intramuscular artemether probably results in fewer deaths than treatment with quinine (RR 0.59, 95% CI 0.42 to 0.83; four trials, 716 participants, moderate quality evidence). Artemether versus artesunate Artemether and artesunate have not been directly compared in randomized trials in African children.For adults in Asia, mortality is probably higher with intramuscular artemether (RR 1.80, 95% CI 1.09 to 2.97, two trials,494 participants, moderate quality evidence). AUTHORS'
CONCLUSIONS: Although there is a lack of direct evidence comparing artemether with artesunate, artemether is probably less effective than artesunate at preventing deaths from severe malaria. In circumstances where artesunate is not available, artemether is an alternative to quinine.

Summary of findings

Background

Description of the condition

Malaria is a febrile illness caused by Plasmodium parasites, which are transmitted to humans through the bite of infected female anopheline mosquitoes. Five species of Plasmodium cause this disease in humans, of which P. falciparum is the most common worldwide, and is responsible for almost all of the severe disease and deaths (WHO 2000; WHO 2008).

Severe malaria is diagnosed on the basis of a positive blood slide or antigen test for malaria, plus the presence of clinical or laboratory features of vital organ dysfunction. These include impaired consciousness, coma, convulsions, respiratory distress, shock (systolic blood pressure < 70 mmHg in adults, < 50 mmHg in children), jaundice, haemoglobinuria, hypoglycaemia, severe metabolic acidosis or anaemia (WHO 2010). Cerebral malaria is one form of severe malaria, where the patient has some impairment of consciousness and cognition. This can vary from slight disorientation through to deep coma where the patient is unconscious and unrousable. Even with correct treatment cerebral malaria can cause a mortality rate of up to 20%, and a small proportion of people that survive infection can have persistent neurological sequelae (Jaffar 1997).

People living in malaria‐endemic regions can develop a naturally acquired immunity to malaria through repeated exposure to the parasite over five to 10 years (Doolan 2009). This partial immunity is protective against the most severe forms of the disease, and as a consequence, in high transmission settings mortality from severe malaria is highest in young children and decreases with increasing age (WHO 2010).

The World Health Organization (WHO) currently recommends parenteral artesunate as the first‐line treatment for severe malaria, followed by a complete course of an effective artemisinin‐based combination therapy (ACT) as soon as the patient can take oral medications (WHO 2010). The WHO based their recommendation on evidence from two large multi‐centre clinical trials that demonstrated the superiority of intravenous artesunate over the standard treatment quinine (Dondorp 2005; Dondorp 2010). A Cochrane Review of available data concluded that treating people that have severe malaria with artesunate instead of quinine would reduce the risk of death by 39% in adults and 24% in children (Sinclair 2011).

Description of the intervention

Artesunate is only one of a number of antimalarials derived from artemisinin, which is extracted from the herb Artemesia annua and is the active ingredient in a Chinese herbal remedy for fever. Once ingested or injected, artemisinin derivatives undergo conversion to dihydroartemisinin, the active metabolite, which has a broad spectrum of activity against the blood stage asexual Plasmodium parasites (Navaratnam 2000; ter Kuile 1993). Artemisinin derivatives clear parasites from the peripheral blood quicker than other antimalarials, but only artesunate has been shown to impact mortality.

Unlike artesunate, artemether is poorly soluble in water and the parenteral formulation is only available as a pre‐mixed oil‐based solution for intramuscular injection (80 mg/mL for use in adults and 40 mg/mL for children). The standard dose is 3.2 mg/kg on admission followed by 1.6 mg/kg once daily until oral therapy is tolerated (WHO 2010). Peak plasma concentrations typically occur around six hours after intramuscular injection, but in severely ill children with poor peripheral perfusion, absorption can be highly erratic (Karbwang 1997; Mithwani 2004; Murphy 1997).

Conversely, artesunate is supplied as a dry powder for mixing with sodium bicarbonate prior to either intravenous or intramuscular injection (WHO 2010). Compared with artemether, the absorption of artesunate is more reliable with peak plasma concentrations following intramuscular injection occurring at around one hour (Hien 2004; Illet 2002; Nealon 2002). These more favourable pharmacokinetic properties of artesunate moved research attention away from artemether and artesunate now has a stronger evidence‐base and is the preferred therapy (Sinclair 2011; WHO 2010).

Why it is important to do this review

A number of African countries incorporated intramuscular artemether into their national guidelines prior to the WHO recommendation for artesunate. Systematic reviews concluded that intramuscular artemisinin derivatives (including both artesunate and artemether) were not inferior to quinine in preventing deaths from malaria, but were safer and easier to administer (AQMSG 2001; Kyu 2009; McIntosh 2000).

Following the WHO recommendation for artesunate as the preferred treatment for severe malaria, there is a need to re‐evaluate the role of intramuscular artemether in the management of severe malaria in adults and children.

Objectives

To assess the efficacy and safety of intramuscular artemether versus any other parenteral medication in the treatment of severe malaria in adults and children.

Methods

Criteria for considering studies for this review

Types of studies

Randomized controlled trials (RCTs).

Types of participants

Adults and children (under 15 years of age) with severe malaria.

Types of interventions

Intervention

Intramuscular artemether

Control

Any other parenteral medication for the treatment of severe malaria

Types of outcome measures

Primary outcomes

Death from any cause

Secondary outcomes

Coma resolution time

Neurological sequelae (such as blindness, deafness, hemiplegia and others)

Time to hospital discharge

Parasite clearance time

Fever clearance time

Need for blood transfusion

Severe anaemia

Adverse events (including hypoglycaemia, tinnitus, nausea, vomiting, haematological and cardiac‐related adverse events)

Search methods for identification of studies

We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press and in progress).

Electronic searches

Databases

We searched the following databases on 09 April 2014 using the search terms detailed in Table 6:  Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 4), published in The Cochrane Library; MEDLINE (1966 to April 2014); EMBASE (1974 to April 2014), LILACS (1982 to April 2014) and ISI Web of Science (1900 to April 2014). We also searched the WHO clinical trial registry platform, ClinicalTrials.gov and the metaRegister of Controlled Trials (mRCT) up to 09 April 2014 for ongoing trials using 'artemether', 'severe malaria', 'complicated malaria', 'artesunate', 'arteether', and 'child*' as search terms.

Table 1

Search strategy

Search set	CIDG SR1	CENTRAL	MEDLINE2	Embase2	LILACS2	ISI Web of Science
1	malaria	Malaria ti, ab, MeSH	Malaria ti, ab, MeSH	Malaria ti, ab, Emtree	malaria	malaria
2	artemether	Artemether ti, ab	Artemether ti, ab	Artemether ti, ab, Emtree	artemether	artemether
3	Artemisinin*	Artemisinin* ti, ab	Artemisinin* ti, ab	Artemisinin* ti, ab	Artemisinin*	Artemisinin*
4	intramuscular	Intramuscular ti, ab	Intramuscular ti, ab	Intramuscular ti, ab	intramuscular	intramuscular
5	parenteral	Injections, Intramuscular [MeSH]	Injections, Intramuscular [MeSH]	Intramuscular drug administration [Emtree]	parenteral	parenteral
6	2 or 3	Parenteral ti, ab	Parenteral ti, ab	Parenteral drug administration [Emtree]	2 or 3	2 or 3
7	4 or 5	2 or 3	2 or 3	2 or 3	4 or 5	4 or 5
8	1 and 5 and 7	4 or 5 or 6	4 or 5 or 6	4 or 5 or 6	1 and 5 and 7	1 and 5 and 7
9	‐	1 and 7 and 8	1 and 7 and 8	1 and 7 and 8	‐	Randomised clinical trial*
10	‐	‐	‐	‐	‐	8 and 9

1Cochrane Infectious Diseases Group Specialized Register. 2Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Lefebvre 2011).

Searching other resources

Conference proceedings

We searched relevant proceedings of the following meetings for trial information; Multilateral Initiative on Malaria (MIM) Pan‐African Malaria Conference, European Congress of Tropical Medicine and American Society of Tropical Medicine and Hygiene (09 April 2014).

Researchers

We contacted researchers working in the field and the WHO for unpublished and ongoing trials.

Reference lists

We checked the reference lists of existing reviews and of all trials identified by the above methods.

Data collection and analysis

Selection of studies

Two authors (EE and EEE) independently screened the literature search results and obtained the full reports of such potentially relevant trials. EE and EEE independently applied the inclusion criteria to the full reports using an eligibility form and scrutinized publications to ensure each trial was included only once. We resolved any disagreements through discussion with a third author and, when necessary, by consulting a member of the Cochrane Infectious Diseases Group (CIDG) editorial team. Also, we listed the excluded studies and the reasons for their exclusion.

Data extraction and management

EE and EEE independently extracted data using a specifically developed piloted data extraction form. We resolved any disagreements through discussion with all of the review authors and, when necessary, by consulting a member of the CIDG editorial team. We contacted the corresponding publication author in the case of unclear information or missing data. For each outcome we aimed to extract the number of participants randomized and the number analysed in each treatment group. For dichotomous outcomes, we recorded the number of participants experiencing the event and the number assessed in each treatment group. For continuous outcomes, we extracted arithmetic means and standard deviations for each treatment group, together with the numbers assessed in each group.

Where baseline proportions of participants in the intervention and control arms in whom antipyretics were administered varied, we only included trials that reported fever clearance time and provided additional information about antipyretics use at baseline for participants in both intervention and control arm to avoid confounding in the summary estimate for fever clearance. Where there was significant difference between antipyretic use at baseline in intervention and control arms, we only reported fever clearance time in a table. We defined cure rates in this review as time from first dose to first negative parasite reading for two consecutive readings.

Assessment of risk of bias in included studies

EE and EEE independently assessed the risk of bias of each trial using a risk of bias form. We attempted to contact the trial authors if this information was not specified or if it was unclear. We resolved any disagreements by discussion between review authors. Six components were assessed: generation of the randomization sequence, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other biases (such as the trial stopped early). We categorized our judgements as either 'low', 'high', or 'unclear' risk of bias, and described our reasons for doing so.

Measures of treatment effect

We calculated results using risk ratios for dichotomous data, and mean difference values for continuous data, and presented these effect estimates with 95% confidence intervals (CI). We treated time‐to‐event outcomes as continuous data and accordingly mean difference calculated from mean time in intervention versus control groups.

Unit of analysis issues

For multiple arm trials, we combined all relevant experimental intervention groups of the trial into a single group, and also combined all relevant control intervention groups into a single control group. For dichotomous outcomes, both the sample sizes and the numbers of people with events were added across groups. For continuous outcomes, we combined means and standard deviations using methods described in the Cochrane Handbook for Systematic Reviews of Interventions.

Dealing with missing data

We analysed data according to the intention‐to treat principle (all randomized participants should be analysed in the groups to which they were originally assigned). If there were discrepancies between the number randomized and the number analysed, we calculated the percentage loss to follow‐up for each treatment group and reported this information.

However, if for some trials it was unclear whether there was loss to follow‐up, we entered the number analysed into Review Manager (RevMan) whenever these figures were available. By attempting to carry out a complete case analysis, we avoided making assumptions about the outcomes of participants lost to follow‐up. Where possible, we contacted authors for missing data.

Assessment of heterogeneity

We looked for statistical heterogeneity by inspecting the forest plots for overlapping CIs, applying the Chi2 test (P < 0.10 considered statistically significant) and the I2 statistic (I2 value < 50% used to denote moderate levels of heterogeneity).

Assessment of reporting biases

We planned to construct funnel plots to look for evidence of publication bias provided we included a sufficient number of trials to make this informative.

Data synthesis

We analysed the data using Review Manager (RevMan). In the first instance, we applied a fixed‐effect meta‐analysis. However, if we detected moderate heterogeneity but still considered it appropriate to combine the trials, we then used a random‐effects approach. Where heterogeneity was very high such that meta‐analysis was not appropriate, we displayed the results in forest plots or tables but did not combine the results. Where data were only presented as medians and ranges, we presented the results in tables.

We presented the main results of the review alongside a GRADE appraisal of the quality of evidence in the 'Summary of Findings' tables.

Subgroup analysis and investigation of heterogeneity

We grouped the analysis and results by children and adults. We reported results by whether the studies were carried out in Africa or in Asia. We examined whether loading dose or quinine influenced outcomes.

Sensitivity analysis

We conducted a sensitivity analysis to investigate the robustness of the results to the risk of bias components by including only trials that concealed the allocation and had low incomplete outcome data (< 10%).

Assessment of the quality of evidence

We assessed the quality of the evidence following the GRADE approach and defined 'quality' as an assessment of our confidence in the estimates of effect (Guyatt 2008).

Results

Description of studies

See the Characteristics of included studies section for details of the included trials.

Results of the search

We conducted the literature search up to 09 April 2014 and identified 77 references (see Figure 1).

Figure 1

Study flow diagram.

Included studies

We included 18 RCTs, enrolling 2662 participants, in this review. Twelve trials enrolled children only (1447 participants aged between six months and 15 years), and six trials enrolled older children and adults (1215 participants aged between 13 and 79 years).

Location

The trials in children were primarily conducted in Africa: Nigeria (five trials), Sudan (two trials), the Gambia (one trial), Kenya (one trial), Malawi (one trial), and Mali (one trial); with only one trial from Asia (India).

Five adult trials were conducted in Asia: Vietnam (three trials), and Thailand (two trials); and one in Oceania; Papua New Guinea (one trial). We have attached a three letter country code to each trial ID to aid forest plot interpretation.

Interventions

All 12 trials in children compared artemether with quinine. Artemether was given by intramuscular injection, with a loading dose of 3.2 mg/kg body weight followed by maintenance doses of 1.6 mg/kg for three to six days (see Table 7 for details). Only three trials followed this with oral therapy once tolerated (Murphy 1996 KEN; Taylor 1998 MWI; van Hensbroek 1996 GMB). For quinine, nine trials administered the WHO recommended loading dose of 20 mg/kg of intravenous or intramuscular quinine followed by a maintenance dose of 10 mg/kg. However, van Hensbroek 1996 GMB administered the maintenance dose at 12‐hourly intervals instead of eight‐hour intervals (see Table 7).

Table 2

Characteristics of trials comparing artemether and quinine in children

Trial ID	Year of study	Age limits	Quinine dosing schedule			Artemether dosing schedule
			Loading dose	Maintainance	Follow‐on therapy	Loading dose	Maintainance	Follow‐on therapy
Adam 2002 SDN	2002	'Children'	20 mg/kg IV	10 mg/kg IV every eight hours for 72 hours	Oral quinine for 7 days	3.2 mg/kg IM	1.6 mg/kg IM once daily for 4 days	None
Aguwa 2010 NGA	2007	6 months to 12 yrs	20 mg/kg IV or IM	10 mg/kg IV/IM every eight hours	None	3.2 mg/kg IM	1.6 mg/kg IM once daily for 2 days	None
Huda 2003 IND	2001	< 14 yrs	20 mg/kg IV	10 mg/kg IV every eight hours	Quinine to complete 7 days	1.6 mg/kg IM twice daily	1.6 mg/kg IM once daily for 5 days	None
Minta 2005 MLI	2004	3 months to 15 yrs	20 mg/kg IV	10 mg/kg IV every eight hours	Quinine 10 mg/kg every eight hours	3.2mg/kg IM twice daily	1.6 mg/kg IM once daily for 4 days	None
Murphy 1996 KEN	1996	5 months to 12 yrs	20 mg/kg IV	10 mg/kg IV every eight hours	SP once	3.2 mg/kg IM	1.6 mg/kg IM once daily for 4 days	SP once
Ojuawo 1998 NGA	1998	Mean age about 4 yrs	10 mg/kg IV	10 mg/kg IV every eight hours	Quinine to complete 7 days	3.2 mg/kg IM	1.6 mg/kg IM 12 hrs later, then once daily for 2 days	None
Olumese 1999 NGA	1999	11 months to 5 yrs	20mg/kg IV	10mg/kg IV every eight hours	Quinine to complete 7 days	3.2 mg/kg IM	1.6 mg/kg IM once daily for 4 days	None
Osonuga 2009 NGA	2009	1 to 12yrs	10 mg/kg IV	10 mg/kg IV every eight hours	Quinine to complete 7 days	1.6 mg/kg IM twice daily	1.6 mg/kg IM once daily for 4 days	None
Satti 2002 SDN	1996	3 months to 15yrs	10 mg/kg IV	10 mg/kg IV every eight hours	Quinine to complete 7 days	1.6 mg/kg IM twice daily	1.6 mg/kg IM once daily for 4 days	None
Taylor 1998 MWI	1994	Mean age of 3 yrs	20 mg/kg IV	10 mg/kg IV every eight hours for at least 2 doses	SP once	3.2 mg/kg IM	1.6 mg/kg IM once daily for 2 days at least	SP once
van Hensbroek 1996 GMB	1994	1 to 9yrs	20 mg/kg IV	10 mg/kg IV every twelve hours	Quinine to complete 5 days	3.2 mg/kg IM	1.6 mg/kg IM once daily for 3 days	SP once1
Walker 1993 NGA	1993	1 to 5yrs	20 mg/kg IV	10 mg/kg IV every eight hours	Quinine to complete 7 days	3.2 mg/kg IM	1.6 mg/kg IM once daily for 4 days	None

IM = intramuscular; IV = intravenous; SP = sulphadoxine‐pyrimethamine.

1Only in the second and third years of the study.

In adults, four trials compared artemether with quinine (Hien 1996 VNM; Karbwang 1992 THA; Karbwang 1995 THA; Seaton 1998 PNG) and two trials compared artemether with artesunate (Phu 2010 VNM; Vinh 1997 VNM). Artemether was given intramuscularly, over three to seven days with slight variations in dosing (see Table 8 and Table 9) and all four trials administered quinine at the WHO‐recommended loading dose.

Table 3

Characteristics of trials comparing artemether and quinine in adults

Trial ID	Year of study	Age limits	Quinine dosing schedule			Artemether dosing schedule
			Loading dose	Maintainance	Follow‐on therapy	Loading dose	Maintainance	Follow‐on therapy
Hien 1996 VNM	1996	15 to 79 yrs	20 mg/kg IM	10 mg/kg IM every eight hours	Quinine or mefloquine to complete 7 days	4 mg/kg IM	2 mg/kg IM once daily for 4 days	Quinine or mefloquine to complete 7 days
Karbwang 1992 THA	1991	15 to 45 yrs	20 mg/kg IV	10 mg/kg every eight hours for 7 days	Quinine to complete 7 days	160 mg IM	80 mg IM once daily for 6 days	None
Karbwang 1995 THA	1994	15 to 55 yrs	20 mg/kg IV	10 mg/kg every eight hours for 7 days	Quinine to complete 7 days	160 mg IM	80 mg IM once daily for 6 days	None
Seaton 1998 PNG	1995	> 12 yrs	20 mg/kg IV	10 mg/kg IV every eight hours	Quinine to complete 7 days	3.2 mg/kg IM	1.6 mg/kg IM once daily for 4 days	None

IM = intramuscular; IV = intravenous.

Table 4

Characteristics of studies comparing artemether and artesunate in adults

Trial ID	Year of study	Age limits	Artemether dosing schedule			Artesunate dosing schedule
			Loading dose	Maintainance	Follow‐on therapy	Loading dose	Maintainance	Follow‐on therapy
Phu 2010 VNM	2003	15 to 77 yrs	3.2 mg/kg IM	1.6 mg/kg IM daily	None	2.4 mg/kg IM	1.2 mg/kg IM once daily	2 mg/kg of artesunate to complete 7 days
Vinh 1997 VNM	1994	15 to 66 yrs	200 mg IM	100 mg IM once daily for 3 days	Mefloquine once	120 mg IM or IV	60 mg IM or IV once daily for 3 days	Mefloquine once

IM = intramuscular; IV = intravenous.

Supportive care

All 12 trials in children reported measurement of blood glucose on admission, but only nine trials reported any subsequent active monitoring for hypoglycaemia.

Only one trial in adults reported measuring blood glucose on admission and monitored hypoglycaemia up to 24 hours after admission (Hien 1996 VNM).

Outcome measures

All 18 trials reported death, a measure of coma resolution, fever clearance and parasite clearance as outcomes. Eleven trials reported neurological sequelae at discharge. Only two trials (Aguwa 2010 NGA; Phu 2010 VNM) reported duration of hospital stay and two trials (Hien 1996 VNM; Olumese 1999 NGA) reported on the number of children requiring blood transfusions. Eleven trials (Adam 2002 SDN; Hien 1996 VNM; Huda 2003 IND; Karbwang 1992 THA; Karbwang 1995 THA; Minta 2005 MLI; Murphy 1996 KEN; Phu 2010 VNM; Seaton 1998 PNG; van Hensbroek 1996 GMB; Walker 1993 NGA) reported on adverse events including episodes of hypoglycaemia. We have listed the outcome definitions used in the included trials in Table 10.

Table 5

Definitions of outcome measures used in the review

Trial ID	Coma resolution time	Fever clearance time	Parasite clearance time	Hypoglycaemia
Adam 2002 SDN	Mean value (h) reported and defined as a Blantyre coma score of 5 recorded for at least 24 hours	Mean value (h) reported and defined as the time after which the temperature remained normal (axillary temperature < 37.5°C)	Mean value (h) reported and defined as the time passed from admission and start of treatment until two consecutive negative smears. Blood films repeated every 8 hours.	Number of episodes (n/N) reported but not defined
Aguwa 2010 NGA	Proportions with coma resolution on D3 reported but not defined	Proportions with fever clearance on D3 and D14 reported and defined as body temperature ≤ 37.5°C after commencement of treatment	Proportions with parasite clearance on D3 and D14. Parasite clearance was taken as adequate clinical and parasitological response (ACPR) at days 3 and 14. Parasite count taken on D0, D3 and D14.	Not reported
Hien 1996 VNM	Median value (h) reported and defined as the time to reach a score of 15 on the Glasgow Coma Scale	Median value (h) reported but not defined.	Median value (h) reported and defined as the time to Assessed every 4 hours for the first 24 hours and every 6 hours until three consecutive negative blood smears	Number of episodes (n/N) reported but not defined
Huda 2003 IND	Glasgow coma scale was used in grading the level of consciousness of the patientsevery eight hours	Mean value (h) reported and defined as time to clearance of fever	Mean value (h) reported but not defined	Not reported
Karbwang 1992 THA	Unclear if values reported are means or medians (h)	Mean value (h) reported and defined as time for the temperature to fall below 37.5°C and remain that value for 72 hours	Mean value (h) reported and defined as the time for the parasite count to fall below the level of microscopic detection (thick film)	Not reported
Karbwang 1995 THA	Median value (h) reported and defined as the time taken for the patients to recover completely from unconciousness	Mean value (h) reported and defined as time for the temperature to fall below 37.5°C and remain that value for 72 hours	Median value (h) reported and defined as the time taken for parasite count to fall below the level of microscopic detection (thick film)	Not reported
Minta 2005 MLI	Mean value (h) reported and defined as the time to normalization of consciousness	Mean value (h) reported but not defined	Mean value (h) reported and defined as time till negative parasitaemia result	Not reported
Murphy 1996 KEN	Median value (h) reported but not described	Median value (h) reported but not described	Median value (h) reported but not described. Every four hours until clearance	Not reported
Ojuawo 1998 NGA	Mean value (h) reported and defined as the interval between onset of therapy and the attainment of full consciousness	Mean value (h) reported and defined as the interval between the onset of therapy and the time the body temperature is ≤ 37°C and remained so	Defined as two successive thick blood films done at 12 hours interval are negative for asexual forms of plasmodium species	Not reported
Olumese 1999 NGA	Mean value (h) reported and defined as time to regain full consciousness	Mean value (h) reported and defined as the time for temperature to fall below 37.5°C and remain so for at least 48 hours	Mean value (h) reported and defined asthe time from start of drug administration to the first of two consecutive negative thick smears remaining negative until day 7	Not reported
Osonuga 2009 NGA	Mean value (h) reported and defined as time to attainment of a Blantyre score of 5 for at least 24 hours from initiation of treatment	Mean value (h) reported but not defined	Mean value (h) reported but not defined. Thick and thin film done on D0 and repeated on Days 3, 7 and 14	Not reported
Phu 2010 VNM	Median value (h) reported and defined as time to Glasgow coma score of 15.	Median value (h) reported and defined as the time for temperature to fall below 37.5°C and remain so	Median value (h) reported and defined as the time to clear all parasites	Number of episodes (n/N) reported but not defined
Satti 2002 SDN	Mean value (h) reported and defined as time to regaining consciousness	Mean value (h) reported and defined as the time for temperature to fall below 37.5°C	Mean value (h) reported and defined as time to clear parasites measured every six hours till clearance	Not reported
Seaton 1998 PNG	Median value (h) reported but not defined	Median value (h) reported and defined as a temperature <37.5 °C on two successive readings	Median value (h) reported and defined as as the time at which the blood films were negative for P. falciparum for at least eight hours	Number of episodes (n/N) reported but not defined
Taylor 1998 MWI	Median value (h) reported and defined as time required for achild to achieve a Blantyre Coma Score of 5	Median value (h) reported and defined as the time at which the rectal or axillary temperature dropped below 37.5°C and remained < 37.5°C for 24 consecutive hours	Median value (h) reported and defined as the time at which the first of two negative (0 parasites/200 WBC) thick blood films was prepared. Every four hours till clearance	Not reported
van Hensbroek 1996 GMB	Median value (h) reported and defined as time to regain full consciousness	Median value (h) reported and defined as time needed for the rectal temperature to fall below 38.0°C for at least 24 hours	Median value (h) reported and defined as time needed for all parasites to clear relative to parasite density at admission and assessed every 12 hours till clearance	Number of episodes (n/N) reported and defined as a blood glucose level below 40 mg/dL (2.2 mmol/L)
Vinh 1997 VNM	Median value (h) reported and defined as time to regain full consciousness	Median value (h) reported and defined as time for axillary temperature to fall to, and remain for ≥ 24 hours at 37.5°C or lower	Median value (h) reported and defined as time to clear parasites	Not reported
Walker 1993 NGA	Mean value (h) reported but not defined	Mean value (h) reported	Mean value (h) reported and defined as the time for parasitaemia to be cleared and to remain so up to Day 7. Assessed every six hours during period of coma and then every 12 hours.	Not reported

WBC = white blood cell.

Other outcomes reported by trials which we did not include in this review were time to death (Murphy 1996 KEN; Taylor 1998 MWI; van Hensbroek 1996 GMB), survival rate (Karbwang 1992 THA; Karbwang 1995 THA), cause of death (Karbwang 1992 THA), fatality rate (Vinh 1997 VNM), time to ambulation (Olumese 1999 NGA; Phu 2010 VNM), time to sit unaided and time to drink (Phu 2010 VNM; Walker 1993 NGA), time to eating (Phu 2010 VNM), gametocyte carriage (Adam 2002 SDN), recrudescence (Adam 2002 SDN; Minta 2005 MLI; Taylor 1998 MWI; Walker 1993 NGA), 28th day cure rate (Satti 2002 SDN; van Hensbroek 1996 GMB; Walker 1993 NGA). Other outcomes included duration of parenteral treatment and time for plasma lactate levels to fall below 2.5 mmol/L (Hien 1996 VNM).

Excluded studies

We excluded 14 trials and listed the reasons for their exclusion in the 'Characteristics of excluded studies' section.

Risk of bias in included studies

See Figure 2 for a summary of the risk of bias assessments. We presented further details in the 'Characteristics of included studies' tables.

Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included trial.

Allocation

Seven trials were at low risk of bias regarding the generation of allocation sequence while one trial was at high risk of bias (Aguwa 2010 NGA). Ten trials were at unclear risk of bias because review authors did not provide enough information to permit us to make a judgement.

Eleven trials were at low risk of bias regarding allocation concealment and the remaining trials provided insufficient information to make a judgement.

Blinding

In all trials, except Hien 1996 VNM and Phu 2010 VNM, investigators and participants were aware of treatment allocation. Participants were also not blind to the intervention as two different routes (intramuscular (artemether) and intravenous (quinine) were used to administer the interventions. Blinding was unlikely to affect the assessment of outcome death in all trials. In one trial, microscopists were blinded to the intervention and clinical status of the patients (Huda 2003 IND). The other subjective outcomes were thus at high risk of bias in all open included trials or at unclear risk of bias where trial provided did not provide information.

Incomplete outcome data

Fourteen trials reported no losses to follow‐up. The remaining four trials (Aguwa 2010 NGA; Satti 2002 SDN; Seaton 1998 PNG; Taylor 1998 MWI) reported over 10 per cent attrition in either one or both trial arms. Two trials used the per protocol number of participants as a denominator in the analysis (Taylor 1998 MWI; Seaton 1998 PNG). The other two trials used the number of participants randomized as the denominator in the analysis.

Selective reporting

We did not detect any evidence of selective outcome reporting.

Other potential sources of bias

We did not identify any other sources of bias.

Effects of interventions

See: Table 1; Table 2; Table 3

Summary of findings for the main comparison

Summary of findings table 1

Artemether compared with quinine for treating children with severe malaria
Patient or population: Children with severe malaria Settings: Malaria‐endemic countries Intervention: Intramuscular artemether Comparison: Intravenous or intramuscular quinine
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (trials)	Quality of the evidence (GRADE)
	Assumed risk	Corresponding risk
	Quinine	Artemether
Death	170 per 1000	164 per 1000 (129 to 204)	RR 0.96 (0.76 to 1.2)	1447 (12 trials)	⊕⊕⊕⊝ moderate1,2,3,4
Coma resolution time	The mean coma resolution time ranged across control groups from 17.4 to 42.4 hours	The mean coma resolution time in the intervention groups was 5.45 hours shorter (7.90 to 3.00 shorter)	‐	358 (6 trials)	⊕⊕⊝⊝ low3,5,6,7
Neurological sequelae at discharge	220 per 1000	185 per 1000 (145 to 235)	RR 0.84 (0.66 to 1.07)	968 (7 trials)	⊕⊕⊝⊝ low 1,2,3,8
Parasite clearance time	The mean parasite clearance time ranged across control groups from 22.4 to 61.25 hours	The mean parasite clearance time in the intervention groups was 9.03 hours shorter (11.43 to 6.63 shorter)	‐	420 (7 trials)	⊕⊕⊕⊝ moderate1,3,7,9
Fever clearance time	The mean fever clearance time ranged across control groups from 18 to 61.25 hours	The mean fever clearance time in the intervention groups was 3.73 shorter (6.55 to 0.92 shorter)	‐	457 (8 trials)	⊕⊕⊝⊝ low3,10,11,12
*The assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.

1 No serious risk of bias: Trials were variable in their risk of bias, but exclusion of the trials at high or unclear risk of selection bias did not change this result. 2 No serious inconsistency: None of the individual trials found statistically significant effects, and there was no statistical heterogeneity between trials. 3 No serious indirectness: Trials were from West Africa, East Africa and one from India. All were in children with severe malaria (aged under 15 years), and most compared the standard dose of intramuscular artemether with the WHO recommended dose of intravenous quinine. 4 Downgraded by 1 for serious imprecision: These trials, and the overall meta‐analysis are underpowered to detect a difference or to prove equivalence. 5 Downgraded by 2 for serious risk of bias: Four of the six trials were at unclear risk of selection bias. When these four trials are excluded the result becomes non‐significant. 6 No serious inconsistency: Statistically significant differences were only seen in two of the six trials. However, statistical heterogeneity between trials was low and the overall meta‐analysis is statistically significant. 7 No serious imprecision: The result is statistically significant and the overall meta‐analysis is adequately powered to detect this effect. 8 Downgraded by 2 for very serious imprecision: These trials, and the overall meta‐analysis are underpowered to detect a difference or to prove equivalence. The 95% CI is very wide and includes clinically important differences and no effect. 9 Downgraded by 1 for serious inconsistency: The mean difference in parasite clearance time ranged from a two hour increase with artemether to a 15 hour decrease. 10 Downgraded by 1 for serious risk of bias: Four of the seven trials were at unclear risk of selection bias. When these four trials are excluded the result becomes non‐significant. 11 Downgraded by 1 for serious inconsistency: The mean difference in fever clearance time ranged from a 25 hour increase with artemether to an 18 hour decrease. 12 No serious imprecision: The overall meta‐analysis is powered to detect this effect. The result is statistically significant but may not be clinically important.

Summary of findings 2

Summary of findings table 2

Artemether compared with quinine for treating adults with severe malaria
Patient or population: Adults with severe malaria Settings: Malaria endemic countries Intervention: Intramuscular artemether Comparison: Intravenous or intramuscular quinine
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (trials)	Quality of the evidence (GRADE)
	Assumed risk	Corresponding risk
	Quinine	Artemether
Death	208 per 1000	123 per 1000 (87 to 173)	RR 0.59 (0.42 to 0.83)	716 (4 trials)	⊕⊕⊕⊝ moderate1,2,3,4
Coma resolution time	‐	‐	Not pooled. Little difference.	657 (2 trials)	⊕⊕⊝⊝ low1,5,6, 7
Neurological sequelae at discharge	4 per 1000	12 per 1000(1 to 111)	RR 2.92 (0.31 to 27.86)	560 (1 trial)	⊕⊕⊝⊝ low7,8
Parasite clearance time	‐	‐	Not pooled. Little difference apparent.	716 (4 trials)	⊕⊕⊕⊝ moderate1,3,6,9
Fever clearance time	‐	‐	Not pooled. Little difference apparent.	716 (4 trials)	⊕⊕⊝⊝ low1,3,6,10
*The assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.

1 No serious risk of bias: Trials are generally well conducted and at low risk of bias. 2 No serious inconsistency: Statistically significant differences were only seen in one of the four trials. However, statistical heterogeneity between trials was low and the overall meta‐analysis is statistically significant. 3 No serious indirectness: All four trials compared intramuscular artemether with intravenous quinine in adults; two trials from Thailand, one each from Vietnam and Papua New Guinea 4 Downgraded by 1 for serious imprecision: These trials, and the overall meta‐analysis are very underpowered to detect a difference in mortality or to prove equivalence. 5Hien 1996 VNM and Karbwang 1995 THA reported median coma time for artemether vs. quinine (Hien 1996 VNM: 66 vs. 48, P = 0.003; Karbwang 1995 THA: 48 vs. 48). Downgraded by 1 for inconsistency: One trial found a shorter median coma resolution time with quinine, and one trial found no difference. 6 Downgraded by 1 for imprecision: The data could not be pooled.

7 No serious risk of bias: This single trial was at low risk of bias.

8 Downgraded by 1 for serious imprecision: Neurological sequelae in adults were uncommon. This trial is underpowered to detect or exclude clinically important differences. 9 Two trials found no significant difference between parasite clearance time for artemether vs. quinine (Karbwang 1992 THA: mean 63.6 vs. 61.6, P = 0.85 and Seaton 1998 PNG: median 48 vs. 52, P = 0.381). Two other trials reported significantly shorter median parasite clearance times for artemether vs. quinine (Hien 1996 VNM: 72 vs. 90 P < 0.001 and Karbwang 1995 THA: 54 vs.78, P = 0.007). No serious inconsistency: The two largest trials both found shorter median clearance times with artemether. 10 Three trials (Hien 1996 VNM, Seaton 1998 PNG and Karbwang 1995 THA) reported median fever clearance time for artemether vs. quinine (127 vs. 90, P < 0.001; 32 vs. 48, P =  0.034 and 79 vs. 84, no significant difference). Karbwang 1992 THAreported mean fever clearance time and found a statistically significant reduction of about 30 hours with artemether. Downgraded by 1 for inconsistency: One trial found a shorter median fever clearance time with quinine, and two trials found a shorter time with artemether.

Summary of findings 3

Summary of findings table 3

Artemether compared with artesunate for treating adults with severe malaria
Patient or population: Adults with severe malaria Settings: Malaria endemic countries Intervention: Intramuscular artemether Comparison: Intravenous or intramuscular artesunate
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (trials)	Quality of the evidence (GRADE)
	Assumed risk	Corresponding risk
	Artesunate	Artemether
Death	87 per 1000	156 per 1000 (95 to 258)	RR 1.80 (1.09 to 2.97)	494 (2 trials)	⊕⊕⊕⊝ moderate1,2,3,4
Coma resolution time	‐	‐	Not pooled. No significant difference	494 (2 trials)	⊕⊕⊕⊝ moderate1,3,5,6
Neurological sequelae at discharge	‐	‐	‐	0 (0 trials)	‐
Parasite clearance time	‐	‐	Not pooled. No significant difference	494 (2 trials)	⊕⊕⊕⊝ moderate1,3,6,7
Fever clearance time	‐	‐	Not pooled. No significant difference	494 (2 trials)	⊕⊕⊝⊝ low1,3,6,8
*The assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.

1 No serious risk of bias: Trials were generally well conducted and at low risk of bias. 2 No serious inconsistency: There is no statistical heterogeneity 3 No serious indirectness: The two trials were conducted in Vietnam and Thailand and both compared intramuscular artemether with intravenous artesunate in adults. 4 Downgraded by 1 for serious imprecision: These trials, and the overall meta‐analysis are very underpowered to detect a difference in mortality or to prove equivalence. 5Phu 2010 VNM and Vinh 1997 VNM reported median coma resolution time for artemether vs. artesunate (Phu 2010 VNM: 72 vs. 60, P = 0.11; Vinh 1997 VNM: 47 (artemether) vs. 30 (artesunate IM) vs. 24 (artesunate IV). No serious inconsistency: Both trials suggest an advantage with artesunate although not statistically significant. 6 Downgraded by 1 for serious imprecision: We could not pool these data as median data were presented for both trials. 7Phu 2010 VNM and Vinh 1997 VNM reported median parasite clearance time (Phu 2010 VNM: 72 vs. 72, P = 0.97; Vinh 1997 VNM: 30 (artemether) vs. 24 (artesunate IM) vs. 24 (artesunate IV). No serious inconsistency: Both trials found no difference between treatments. 8Phu 2010 VNM and Vinh 1997 VNM reported median fever clearance time (Phu 2010 VNM: 108 vs. 108, P = 0.27; Vinh 1997 VNM: 48 (artemether) vs. 36 (artesunate IM) vs. 30 (artesunate IV). No serious inconsistency: Both trials found no statistically significant difference between artemether and artesunate.

Children

Twelve trials were conducted in children, Eleven in Africa and one in Asia. All used loading doses of quinine.

Death: there was no overall difference in all‐cause mortality between intramuscular artemether and intravenous quinine (RR 0.96, 95% CI 0.76 to 1.20; 12 trials, 1447 participants, Analysis 1.1). However, these 12 trials were too small to detect or exclude clinically important differences, and the overall meta‐analysis remains significantly underpowered to prove equivalence (see Table 11 and Table 12). The current total sample size has adequate power to exclude effects as large as seven extra deaths per 100 patients.

Analysis 1.1

Comparison 1 Artemether versus quinine, Outcome 1 Death.

Table 6

Optimal information size calculations; dichotomous outcomes

Outcome	Type of test	Proportion in control group3	Proportion in Intervention group	Estimated RR	Total sample size1,2
Death	Superiority	0.17	0.136	0.80	3514
	Equivalence	0.17	0.14 to 0.204	‐	6592
Neurological sequelae	Superiority	0.25	0.20	0.80	2184
	Equivalence	0.25	0.22 to 0.284	‐	8760

1 These calculation were performed using a power calculator available at: http://www.sealedenvelope.com/power/ 2 All calculation were performed for a power of 80% and an α error of 0.05. 3 The proportion in the control group is taken from the median control group risk across trials. 4 A maximum 3% risk difference was chosen to represent equivalence.

Table 7

Optimal information size calculations; continuous outcomes

Outcome	Type of test	Mean in control group3	Mean in Intervention group4	SD of outcome	Total sample size1,2
Coma resolution time	Superiority	25	19	20	350
	Equivalence	25	19 to 31	20	382
Parasite clearance time	Superiority	42	36	20	350
	Equivalence	42	36 to 48	20	382
Fever clearance time	Superiority	48	42	20	350
	Equivalence	48	36 to 54	20	382

1 These calculations were performed using a power calculator available at: http://www.sealedenvelope.com/power/ 2 All calculation were performed for a power of 80% and an α error of 0.05. 3 The mean in the control group is taken from the median control group across studies. 4 A six‐hour time difference was chosen to represent a clinically important benefit.

Coma resolution time: the mean coma resolution time was about five hours shorter with artemether (26 hours) compared with quinine (30.55 hours) (MD ‐5.45 hours, 95% CI ‐7.90 to ‐3.00; six trials, 358 participants, Analysis 1.3). This effect was largest in trials without adequate allocation concealment and therefore at unclear or high risk of bias. A sensitivity analysis excluding these trials found no significant difference between groups. In addition, three trials reported median time to coma resolution (see Table 13). Two trials found no significant difference (Murphy 1996 KEN; Taylor 1998 MWI), and one trial found the median time to be longer with artemether (26 hours versus 20 hours, P = 0.046, van Hensbroek 1996 GMB). Two other trials (Minta 2005 MLI; Osonuga 2009 NGA) reported mean coma resolution time as mean (SD) but the data was not normally distributed and so we have reported this an additional table (Table 13).

Analysis 1.3

Comparison 1 Artemether versus quinine, Outcome 3 Coma resolution time (hours).

Table 8

Additional data: Artemether versus quinine in children

Pre‐specified outcome	Trial reported outcome	Trial	No. of participants	Artemether	Quinine	Comparative results reported in article
Coma resolution time (h)	Median(IQR)	Murphy 1996 KEN	160	12 (2.8 to 96)	13 (2.8 to 96)	Not significantly different
	Median(IQR)	van Hensbroek 1996 GMB	576	26 (15 to 48)	20 (12 to 43)	P = 0.046
	Median(IQR)	Taylor 1998 MWI	164	18 (8 to 30)	20 (10 to 54)	Not significantly different
	Coma recovery (%) on Day 3	Aguwa 2010 NGA	90	15.9%	21.4%	RR = 0.763 (95% CI 0.065 to 9.015)
	Mean (SD)	Osonuga 2009 NGA	32	4.5 (13.05)	9 (24.59)	P = 0.523
	Mean (SD)	Minta 2005 MLI	67	30.57 (29.02)	25.15 (31.62)	P = 0.53
Time to hospital discharge	% spending less than one week inhospital	Aguwa 2010 NGA	90	61.76%	71.74%	P = 0.829
Fever clearance (h)	Median(IQR)	Murphy 1996 KEN	160	32 (4 to 86)	32 (4 to 96)	Not significantly different
		van Hensbroek 1996 GMB	576	30 (16 to 48)	33 (12‐60)	P = 0.8
		Taylor 1998 MWI	164	31 (24 to 52)	45 (33 to 60)	"Significant"
	Fever clearance (%) on Day 3	Aguwa 2010 NGA	90	90.0%	87.7%	P = 0.753
Parasite clearance (h)	Median(IQR)	Murphy 1996 KEN	160	39.5 (24 to 45)	48(37 to 56)	P < 0.001
		van Hensbroek 1996 GMB	576	48 (36 to 60)	60 (48 to 72)	P < 0.001
		Taylor 1998 MWI	164	32 (25 to 36)	40 (32 to 48)	'significant'
	Parasite clearance (%) on Day 3	Aguwa 2010 NGA	90	99.0%n = 44	96.8%n = 46	P = 0.422
Needing blood transfusion	‐	van Hensbroek 1996 GMB	‐	‐	‐	"The two groups were similar in terms of the need for blood transfusions,and the incidence of secondary bacterial infections (data not shown)."

IQR = interquartile range.

Neurological sequelae: there was no overall difference in the risk of neurological sequelae at hospital discharge between artemether (185 per 1000) and quinine (220 per 1000) (RR 0.84, 95% CI 0.66 to 1.07; seven trials, 968 participants, Analysis 1.4). Again these trials were too small to enable us to confidently detect or exclude what may be clinically important differences between treatments (see Table 11). The overall meta‐analysis is adequately powered to exclude effects larger than eight additional sequelae per 100 patients.

Analysis 1.4

Comparison 1 Artemether versus quinine, Outcome 4 Neurological sequelae at discharge.

Three trials continued to monitor patients with neurological sequelae after hospital discharge. Satti 2002 SDN found no difference at day seven, Taylor 1998 MWI found most sequelae had resolved and van Hensbroek 1996 GMB found no difference at day 28 (Analysis 1.5).

Analysis 1.5

Comparison 1 Artemether versus quinine, Outcome 5 Neurological sequelae at follow‐up.

Parasite clearance time (PCT): the mean parasite clearance time in children was approximately nine hours shorter with artemether (MD ‐9.03 hours, 95% CI ‐11.43 to ‐6.63; seven trials, 420 participants, Analysis 1.6. The statistical significance of this result remained after we excluded trials at unclear or high risk of selection bias. The mean parasite clearance times for artemether and quinine were 36.25 and 43.18 hours respectively.

Analysis 1.6

Comparison 1 Artemether versus quinine, Outcome 6 Parasite clearance time.

Three additional trials reported median parasite clearance time and all showed a statistically significant benefit with artemether (see Table 13). One trial (Ojuawo 1998 NGA) expressed parasite clearance as the proportion of patients with parasite clearance at 72 hours and at seven days, with no statistically significant differences between groups (see Analysis 1.7). Trials differed with respect to the frequency with which they repeated malaria blood smears (see Table 10).

Analysis 1.7

Comparison 1 Artemether versus quinine, Outcome 7 Proportion with parasite clearance.

Fever clearance time (FCT): eight trials reported mean fever clearance time with a statistically significant reduction of about three hours with artemether overall (MD ‐3.73 hours, 95% CI ‐6.55 to ‐0.92; eight trials, 457 participants, Analysis 1.8). The mean fever clearance times for artemether and quinine were 43.69 and 46.26 hours respectively. However, only two of the individual trials showed a statistically significant difference between the groups. Three trials in children reported median fever clearance time and two trials found no statistically significant difference between the two groups (see Table 13).

Analysis 1.8

Comparison 1 Artemether versus quinine, Outcome 8 Fever clearance time (hours).

The definitions of fever varied across the included trials. Six trials used a cut off of body temperature less than 37.5°C from initiation of treatment to define fever clearance (see Table 10).

Need for blood transfusion: one trial reported on the number of patients requiring blood transfusions for severe malarial anaemia in both artemether and quinine arms (Olumese 1999 NGA) (see Analysis 1.9). No statistically significant difference was observed between both arms (RR 1.27, 95% CI 0.62 to 2.59; 103 participants, one trial).

Analysis 1.9

Comparison 1 Artemether versus quinine, Outcome 9 Need for blood transfusion.

Adverse effects: six trials reported on the frequency of adverse events (Adam 2002 SDN; Huda 2003 IND; Minta 2005 MLI; Murphy 1996 KEN; van Hensbroek 1996 GMB; Walker 1993 NGA). Two trials reported no adverse events had occurred during the trial duration (see Table 14). One trial reported the absence of adverse events in the artemether arm (Minta 2005 MLI). No trial reported discontinuation of medication.

Table 9

Adverse event monitoring and reporting

Study ID	Sample size	Clinical symptoms monitoring	Biochemistry	Haematological	Electrocardiogram	Additional comments on adverse events
Adam 2002 SDN	41	Not reported	Not reported	Not reported	Not reported	"Neurological deficits were not observed in any patient during the follow‐up period"
Aguwa 2010 NGA	90	Not reported	Not reported	Not reported	Not reported	None
Hien 1996 VNM	560	Clinical assessment every 4 hours for the first 24 hours and 6 hourly afterwards	Blood glucose, lactate and cytokine levels measured 4, 8, 12 and 24 hours after admission	Full blood count on admission	Pre‐treatment and 12 hours after initiation of treatment on Day 0, 4 hours after last dose and at discharge	None
Huda 2003 IND	46	Lumbar punctureChest x‐ray on day 0	Blood Glucose, Renal Function Test,Liver Function Test and Serum Electrolyte on Days 0 and 3	Full Blood Count on Days 0 and 3	Day 0	"No serious side effects of either of the drugs were observed in our study...... Closer and more frequent monitoring and larger sample size would have probably revealed more subtle adverse drug effects."
Karbwang 1992 THA	26	Clinical evaluation daily for at least 7 daysLumbar punctureChest x‐ray on day 0	Biochemistry on Days 0, 2, 4 and 7	Full Blood Count on Days 0, 2, 4 and 7	On admission for all patients; then once daily and every six hours for quinine and artemether patients respectively	"The side effects in the quinine group were dizziness and vertigo. No side effects were detected with artemether".
Karbwang 1995 THA	102	Clinical evaluation on admission and twice daily for at least 7 daysLumbar punctureChest x‐ray on day 0	Biochemistry on Days 0, 2, 4 and 7	FBC on Days 0, 2, 4 and 7	On admission for all patients; then once daily and every six hours for quinine and artemether patients respectively	QTc prolongation and tinnitus were the major adverse events in Quinine arm.Mild transient pain at injection site for approximately 15 mins after artemether treatment.
Minta 2005 MLI	67	Clinical examination daily on Days 1 to7, and 14	Blood glucose on Days 1, 2, 3, 5, 7 and 14Urea and Serum Electrolyte, transaminases, phosphatases on Days 1, 3, 5, 7 and 14	FBC on Days 1, 3, 5, 7 and 14	Once daily on Days 1, 3, 5, 7 and 14	None
Murphy 1996 KEN	160	Clinical assessment on admission, then at six, then 12 hour intervals till discharge	Blood glucose, urea, electrolytes, blood gases and when clinically indicated	FBC on Day 0 and when clinically indicatedBlood cultures on Day 0	On admission and at 6, 24, 30, 48 and 54 hours	None
Ojuawo 1998 NGA	37	Clinical assessment on Day 0	Urea and electrolyteBlood sugar and liver function test on Day 0	FBC on Day 0	None	None
Olumese 1999 NGA	103	Clinical assessments on Days 0, 3, 7, 14, 28	Blood glucose, Urea and creatinine, electrolytes on Days 0, 3, 7, 14, 28	WBC count on Days 0, 3, 7, 14, 28	None	"No adverse reactions to the two drugs were recorded during the study".
Osonuga 2009 NGA	32	Clinical examination on Days 0 to 7 and 14	None	None	None	None
Phu 2010 VNM	370	Clinical examination on admissionChest x‐ray on admissionLumbar puncture	Blood urea nitrogen, serum creatinine, aspartate aminotransferase, alanine transaminase, plasma lactate	Full blood count on admission	None	None
Satti 2002 SDN	77	Clinical evaluation on admission and every six hours on Days 0 to 4, and then once daily on Days 14, 21 and 28	Blood glucose, serum creatinine, serum aspartate, aminotransferase on Day 0	WBC, Haemoglobin on Days 0 and 3	None	None
Seaton 1998 PNG	33	Chest X‐ray on admission	Renal and Liver function tests on admission, Days 3 and 7	Full Blood Count on Days 0, 3 and 7	None	None
Taylor 1998 MWI	183	CSF collected on admission	Blood glucose,Blood pH, on D0 (every four hours for the first 24 hours	Haematocrit every eight hoursFull Blood Count, urea and electrolytes on Days 0, 3, 7 and 28	On admission, 6, 48,54 and 96 hours	"Of the initial 127 patients on whom serial electrocardiographic tracings were made, more patients in the quinine group showed prolongation of the corrected QT intervals after treatment, but the differences were not statistically or clinically significant." "There were no significant differences between the two treatment groups in terms of adverse effects associated with antimalarial treatment (i.e. new signs and symptoms which develop within seven days of the start of treatment)."
van Hensbroek 1996 GMB	576	Clinical examination on Day 0Lumbar puncture on admission	Blood glucose on admission, after 4hours and 12 hours	PCV, Haemoglobin, Blood culture on Day 0	None	None
Vinh 1997 VNM	124	Clinical examination on admission	Blood glucose, serum creatinine, serum bilirubin on admission	Full blood count on admission	None	None
Walker 1993 NGA	54	Clinical examination twice dailySpinal taps	Urea and Electrolyte, on days 3, 7, 14, 28	PCV on days 3, 7, 14, 28	On admission, at 4 and 6 hours	None

Only two trials reported episodes of hypoglycaemia (Analysis 1.10). Other adverse effects reported were QT prolongation, local skin reaction at the injection site, abscess, urticarial rash, pruritus, supraventricular tachycardia and urinary tract infection.. However, these trials were insufficiently powered to detect differences in adverse events. The trials had similar definitions of adverse events (included only adverse effects that could not be attributable to malaria).

Analysis 1.10

Comparison 1 Artemether versus quinine, Outcome 10 Episodes of hypoglycaemia.

Time to hospital discharge: none of the included trials reported time to discharge. One trial reported the proportion of patients that spent less than one week in hospital and found no significant difference between groups (see Table 13).

Adults

Four trials were conducted in adults, three in Asia and one in Oceania. All used loading doses of quinine.

Death: artemether resulted in fewer deaths compared with quinine (RR 0.59, 95% CI 0.42 to 0.83; four trials, 716 participants, Analysis 1.1) from trials conducted mostly in Asia.

Coma resolution time: three trials reported a measure of coma resolution time. Hien 1996 VNM reported median coma resolution time, which was shorter in the quinine arm. Karbwang 1995 THA found both arms to be comparable in terms of coma resolution time. The third trial, Karbwang 1992 THA reported mean coma resolution time but the data were incompletely reported (see Table 15).

Table 10

Additional data: Artemether versus quinine in adults

Pre‐specified outcome	Trial reported outcome	Trial	No. of participants	Artemether	Quinine	Comparative results reported in article
Coma resolution time (h)	Median (IQR)	Hien 1996 VNM	560	66 (30 to 132)	48 (20 to 84)	P = 0.003
	Median (Range)	Karbwang 1995 THA	97	48 (6 to 144)	48 (6 to 144)	Not significantly different
Fever clearance (h)	Median (IQR)	Hien 1996 VNM	560	127 (60 to 216)	90 (54 to 144)	< 0.001
	Median (Range)	Seaton 1998 PNG	33	32 (20 to 112)	48 (28 to 88)	P = 0.034
	Median (Range)	Karbwang 1995 THA	97	79 (16 to 147)	84 (36 to 144)	Not significantly different
Parasite clearance (h)	Median (IQR)	Hien 1996 VNM	560	72 (54 to 102)	90 (66 to 108)	< 0.001
	Median (range)	Seaton 1998 PNG	33	48(4 to 72)	52 (12 to112)	P = 0.381
	Median (Range)	Karbwang 1995 THA	97	54 (30 to 164)	78 (18 to 168)	P = 0.007

IQR = interquartile range.

Neurological sequelae: only one trial Hien 1996 VNM reported neurological sequelae at discharge. Four neurological sequelae were reported with no difference between groups (one trial; 560 participants, Analysis 1.4).

Parasite clearance time (PCT): one trial reported mean parasite clearance time but showed no statistically significant difference between artemether and quinine (MD 1.70 hours, 95% CI ‐15.56 to 18.96; 26 participants, one trial, Analysis 1.6). Three other trials reported median parasite clearance time. Two trials reported a significantly shorter time to clearance of parasites with artemether (Hien 1996 VNM; Karbwang 1995 THA; see Table 13). Seaton 1998 PNG found no significant difference between artemether and quinine with respect to parasite clearance time.

Trials differed with respect to the frequency with which they repeated malaria blood smears (see Table 10).

Fever clearance time (FCT): four trials reported a measure of fever clearance time. Karbwang 1992 THA reported mean fever clearance time and found a statistically significant reduction of about 30 hours with artemether (MD ‐29.7 hours, 95% CI ‐54.14 to ‐5.26; 26 participants, one trial). The other three trials in adults reported median fever clearance time and two (Hien 1996 VNM; Seaton 1998 PNG) reported a statistically significant reduction in fever clearance time in favour of quinine and artemether respectively. Karbwang 1995 THA found both groups were comparable (see Table 15).

The definitions of fever varied across the included trials. Three trials used a cut off of body temperature less than 37.5°C from initiation of treatment to define fever clearance (see Table 10).

Need for blood transfusion: one trial reported on the number of patients requiring blood transfusions for severe malarial anaemia in both artemether and quinine arms (Hien 1996 VNM) (see Analysis 1.9). No statistically significant difference was observed between both arms (RR 0.97, 95% CI 0.73 to 1.29; 560 participants, one trial).

Adverse events: one trial reported episodes of hypoglycaemia (Analysis 1.10). Other adverse effects reported were abscess, induration at injection site, leg discomfort, chest infection and gastrointestinal bleeding. However, these trials were insufficiently powered to detect differences in adverse events. The trials had similar definitions of adverse events (included only adverse effects that could not be attributable to malaria).

Two trials were conducted in adults; both from Asia.

Death: only two trials directly compared intramuscular artemether and intravenous artesunate. Overall, the risk of all‐cause mortality was significantly higher following treatment with artemether (RR 1.80, 95% CI 1.09 to 2.97; 494 participants, two trials, Analysis 2.1). However, both trials were too small to detect or exclude clinically important differences, and the overall meta‐analysis remains significantly underpowered to prove superiority (see Table 11 and Table 12).

Analysis 2.1

Comparison 2 Artemether versus artesunate, Outcome 1 Death.

Coma resolution time: two trials reported median coma resolution times. Both trials reported a shorter coma resolution time with artesunate. However, these differences were not statistically significant (Table 16).

Table 11

Additional data: Artemether versus artesunate in adults

Pre‐specified outcome	Trial reported outcome	Trial	No. of participants	Artemether	Artesunate IM	Artesunate IV	Comparative results reported in article
Coma resolution time (h)	Median (range)	Phu 2010 VNM	370	72(2 to 2232) n = 184	60(4 to 2136) n = 186	‐	P = 0.11
	Median (95% CI)	Vinh 1997 VNM	124	47 (31 to 63)	30 (18 to 42)	24 (4 to 44)	‐
Fever clearance (h)	Median (range)	Phu 2010 VNM	370	108 (0 to 888) n = 184	108 (0 to 888) n = 186	‐	P = 0.27
	Median (95% CI)	Vinh 1997 VNM	124	48 (38 to 58)	36 (30 to 42)	30 (18 to 42)	‐
Parasite clearance (h)	Median (range)	Phu 2010 VNM	370	72(2 to 204)	72(7 to 330)	‐	P = 0.97
	Median (95% CI)	Vinh 1997 VNM	124	30 (26 to 34)	24 (15 to 33)	24 (15 to 33)	Not statistically significant

IM = intramuscular; IV = intravenous.

Parasite clearance time: two trials found no overall difference in median parasite clearance time (Phu 2010 VNM; Vinh 1997 VNM).

Fever clearance time:Phu 2010 VNM found no statistically significant difference in median fever clearance time between intramuscular artemether and intravenous artesunate. The additional small trial (Vinh 1997 VNM) found a benefit in favour of artesunate although this was not statistically significant.

Need for blood transfusion:Phu 2010 VNM found no difference between treatments with respect to the need for blood transfusion in adult severe malaria patients (RR 1.01, 95% CI 0.78 to 1.32; 370 participants, one trial, Analysis 2.2).

Analysis 2.2

Comparison 2 Artemether versus artesunate, Outcome 2 Need for blood transfusion.

Adverse effects: only Phu 2010 VNM reported adverse events. The risk of hypoglycaemia was significantly higher in adults treated with intramuscular artemether compared with artesunate (RR 1.70. 95% CI 0.4 to 7.24; 370 participants, one trial, Analysis 2.4).

Analysis 2.4

Comparison 2 Artemether versus artesunate, Outcome 4 Adverse events.

Discussion

Summary of main results

We included 18 RCTs, enrolling 2662 children and adults with severe malaria. Eleven trials were conducted in Africa and seven trials were undertaken in Asia.

Artemether versus quinine

For children (trials mostly conducted in Africa), there is probably little or no difference in the risk of death between intramuscular artemether and quinine (moderate quality evidence). Artemether may shorten the coma recovery time by about five hours (low quality evidence), and may reduce the number of children with subsequent neurological sequelae (low quality evidence). Artemether probably shortens the parasite clearance time by about nine hours (moderate quality evidence), and may shorten the fever clearance time by about three hours (low quality evidence).

For older children (> 15 years) and adults in Asia, artemether probably reduces deaths compared with quinine (moderate quality evidence), but larger trials are required to have full confidence in this finding.

Artemether versus artesunate

Artemether and artesunate have only been compared in two trials in adults from Asia, and mortality is probably higher with intramuscular artemether (moderate quality evidence) but larger trials are required to have confidence in this finding.

Overall completeness and applicability of evidence

Although 16 trials directly compared artemether versus quinine, none were adequately powered to detect clinically important differences. The total number of participants included in these trials (2163 participants) remains far short of the 7429 participants included in trials of artesunate versus quinine. The majority of data comparing artemether and quinine were from trials conducted in sub‐Saharan Africa where artemether is most widely used.

The two trials directly comparing artemether and artesunate were conducted in adults in Asia, and the results are therefore poorly applicable to children in Africa. However, in the absence of direct comparisons in children, the low quality evidence of equivalence between artemether and quinine suggests that artesunate will be as superior to artemether as it has been shown to be superior to quinine.

Artemether is prone to erratic and partial absorption and takes longer to achieve peak plasma concentrations as demonstrated in animal and human studies. These pharmacokinetic attributes make artemether that is injected intramuscularly less readily available in the human body and may explain the difference in outcomes between artesunate and intramuscular artemether we have observed in this review.

Quality of the evidence

We assessed the quality of the evidence using the GRADE approach and have presented it in three 'Summary of Findings' tables (Table 1; Table 2; Table 3).

The evidence of equivalence between intramuscular artemether and intravenous quinine in children is of moderate quality due to the small sample sizes of the included trials and the overall lack of power to fully exclude clinically important differences.

Similarly, we downgraded the evidence for reductions in mortality in adults treated with artemether compared with quinine, and artesunate compared with artemether, to moderate due to imprecision. Larger trials are needed to have full confidence in these effects.

Authors' conclusions

Although there is a lack of direct evidence comparing artemether with artesunate, artemether is probably less effective than artesunate at preventing deaths from severe malaria. In circumstances where artesunate is not available, artemether is an alternative to quinine.

Larger, adequately powered clinical trials are necessary for conclusive evidence on the relative effects of artemether. However, given the low bioavailability of artemether when given intramuscularly, it is unlikely that these trials will be done or indeed whether they are necessary.

Comparison 1

Artemether versus quinine

Comparison 1 Artemether versus quinine, Outcome 1 Death.

Comparison 1 Artemether versus quinine, Outcome 2 Death: Time since admission to hospital.

Comparison 1 Artemether versus quinine, Outcome 3 Coma resolution time (hours).

Comparison 1 Artemether versus quinine, Outcome 4 Neurological sequelae at discharge.

Comparison 1 Artemether versus quinine, Outcome 5 Neurological sequelae at follow‐up.

Comparison 1 Artemether versus quinine, Outcome 6 Parasite clearance time.

Comparison 1 Artemether versus quinine, Outcome 7 Proportion with parasite clearance.

Comparison 1 Artemether versus quinine, Outcome 8 Fever clearance time (hours).

Comparison 1 Artemether versus quinine, Outcome 9 Need for blood transfusion.

Comparison 1 Artemether versus quinine, Outcome 10 Episodes of hypoglycaemia.

Comparison 1 Artemether versus quinine, Outcome 11 Adverse events.

Comparison 1 Artemether versus quinine, Outcome 1 Death.

Comparison 1 Artemether versus quinine, Outcome 2 Death: Time since admission to hospital.

Comparison 1 Artemether versus quinine, Outcome 3 Coma resolution time (hours).

Comparison 1 Artemether versus quinine, Outcome 4 Neurological sequelae at discharge.

Comparison 1 Artemether versus quinine, Outcome 5 Neurological sequelae at follow‐up.

Comparison 1 Artemether versus quinine, Outcome 6 Parasite clearance time.

Comparison 1 Artemether versus quinine, Outcome 7 Proportion with parasite clearance.

Comparison 1 Artemether versus quinine, Outcome 8 Fever clearance time (hours).

Comparison 1 Artemether versus quinine, Outcome 9 Need for blood transfusion.

Comparison 1 Artemether versus quinine, Outcome 10 Episodes of hypoglycaemia.

Comparison 1 Artemether versus quinine, Outcome 11 Adverse events.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Death Analysis 1.1
16		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 Children	12	1447	Risk Ratio (M‐H, Fixed, 95% CI)	0.96 [0.76, 1.20]
1.2 Adults	4	716	Risk Ratio (M‐H, Fixed, 95% CI)	0.59 [0.42, 0.83]
2 Death: Time since admission to hospital Analysis 1.2
1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 Death within 24 hours	1	41	Risk Ratio (M‐H, Fixed, 95% CI)	0.35 [0.02, 8.10]
3 Coma resolution time (hours) Analysis 1.3
6		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.1 Children	6	358	Mean Difference (IV, Fixed, 95% CI)	‐5.45 [‐7.90, ‐1.00]
4 Neurological sequelae at discharge Analysis 1.4
8		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
4.1 Children	7	968	Risk Ratio (M‐H, Fixed, 95% CI)	0.84 [0.66, 1.07]
4.2 Adults	1	560	Risk Ratio (M‐H, Fixed, 95% CI)	2.92 [0.31, 27.86]
5 Neurological sequelae at follow‐up Analysis 1.5
2	566	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.49, 1.38]
5.1 Day 7	1	134	Risk Ratio (M‐H, Fixed, 95% CI)	0.76 [0.27, 2.14]
5.2 Day 28	1	432	Risk Ratio (M‐H, Fixed, 95% CI)	0.84 [0.46, 1.53]
6 Parasite clearance time Analysis 1.6
8	446	Mean Difference (IV, Fixed, 95% CI)	‐8.82 [‐11.20, ‐6.45]
6.1 Children	7	420	Mean Difference (IV, Fixed, 95% CI)	‐9.03 [‐11.43, ‐6.63]
6.2 Adults	1	26	Mean Difference (IV, Fixed, 95% CI)	1.70 [‐15.56, 18.96]
7 Proportion with parasite clearance Analysis 1.7
1	74	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.75, 1.04]
7.1 At 72 hours	1	37	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.70, 1.11]
7.2 At 7 days	1	37	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.70, 1.11]
8 Fever clearance time (hours) Analysis 1.8
9		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
8.1 Children	8	457	Mean Difference (IV, Fixed, 95% CI)	‐3.73 [‐6.55, ‐0.92]
8.2 Adults	1	26	Mean Difference (IV, Fixed, 95% CI)	‐29.70 [‐54.14, ‐5.26]
9 Need for blood transfusion Analysis 1.9
2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
9.1 Children	1	103	Risk Ratio (M‐H, Fixed, 95% CI)	1.27 [0.62, 2.59]
9.2 Adults	1	560	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.73, 1.29]
10 Episodes of hypoglycaemia Analysis 1.10
3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
10.1 Children	2	617	Risk Ratio (M‐H, Fixed, 95% CI)	0.68 [0.44, 1.05]
10.2 Adults	1	560	Risk Ratio (M‐H, Fixed, 95% CI)	0.44 [0.30, 0.64]
11 Adverse events Analysis 1.11
6		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
11.1 QT prolongation	2	229	Risk Ratio (M‐H, Fixed, 95% CI)	3.10 [1.33, 7.19]
11.2 Local skin reactions	1	576	Risk Ratio (M‐H, Fixed, 95% CI)	0.12 [0.03, 0.50]
11.3 Abscess	2	1136	Risk Ratio (M‐H, Fixed, 95% CI)	0.20 [0.04, 0.90]
11.4 Urticarial rash	1	576	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 8.15]
11.5 Supraventricular tachycardia	1	54	Risk Ratio (M‐H, Fixed, 95% CI)	0.23 [0.01, 4.59]
11.6 Pruritus	1	67	Risk Ratio (M‐H, Fixed, 95% CI)	0.34 [0.01, 8.13]
11.7 Urinary tract infection	1	54	Risk Ratio (M‐H, Fixed, 95% CI)	3.46 [0.15, 81.36]
11.8 Induration at injection site	1	33	Risk Ratio (M‐H, Fixed, 95% CI)	15.44 [0.94, 253.49]
11.9 Leg discomfort	1	560	Risk Ratio (M‐H, Fixed, 95% CI)	0.69 [0.22, 2.16]
11.10 Chest infection	1	560	Risk Ratio (M‐H, Fixed, 95% CI)	1.11 [0.81, 1.53]
11.11 GI bleeding	1	560	Risk Ratio (M‐H, Fixed, 95% CI)	0.79 [0.52, 1.20]

Comparison 2

Artemether versus artesunate

Comparison 2 Artemether versus artesunate, Outcome 1 Death.

Comparison 2 Artemether versus artesunate, Outcome 2 Need for blood transfusion.

Comparison 2 Artemether versus artesunate, Outcome 3 Episodes of hypoglycaemia.

Comparison 2 Artemether versus artesunate, Outcome 4 Adverse events.

Comparison 2 Artemether versus artesunate, Outcome 1 Death.

Comparison 2 Artemether versus artesunate, Outcome 2 Need for blood transfusion.

Comparison 2 Artemether versus artesunate, Outcome 3 Episodes of hypoglycaemia.

Comparison 2 Artemether versus artesunate, Outcome 4 Adverse events.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Death Analysis 2.1
2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 Adults	2	494	Risk Ratio (M‐H, Fixed, 95% CI)	1.80 [1.09, 2.97]
2 Need for blood transfusion Analysis 2.2
1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 Adults	1	370	Risk Ratio (M‐H, Fixed, 95% CI)	1.01 [0.78, 1.32]
3 Episodes of hypoglycaemia Analysis 2.3
1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4 Adverse events Analysis 2.4
1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1 Spontaneous bleeding	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]

Faiz 2001

Methods	RCT
Participants	105 adults enrolled
Interventions	Information not available
Outcomes	Information not available
Notes	Information not available